[Circulating endothelial cells: biomarkers for monitoring activity of antiangiogenic therapy].
Tumor vessel formation is largely dependent on the recruitment of endothelial cells. Rare in healthy individuals, circulating endothelial cells (CEC) are shed from vessel walls and enter the circulation reflecting endothelial damage or dysfunction. Increased numbers of CEC have been documented in different types of cancer. Recent studies have suggested the role for CEC in tumor angiogenesis, but whose presence could also reflect normal endothelium perturbation in cancer. Originating from the bone marrow rather than from vessel walls, endothelial progenitor cells (EPC) are mobilized following tissue ischemia and may be recruited to complement local angiogenesis supplied by existing endothelium. Recently, studies in mouse models suggest that the circulating fraction of endothelial progenitors (CEP) is involved in tumor angiogenesis but their contribution is less clear in humans. The detection of CEC and CEP is difficult and impeded by the rarity of these cells. They may have important clinical implication as novel biomarkers susceptible to predict more efficiently and rapidly the therapeutic response to anti-angiogenic treatments. However, a methodological consensus would be necessary in order to correctly evaluate the clinical interest of CEC and CEP in patients.
Farace
Françoise
F
Laboratoire de recherche translationnelle, Institut de cancérologie Gustave-Roussy, 94805 Villejuif. farace@igr.fr
Bidart
Jean-Michel
JM
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D042783:Endothelial Cells / Q000166:cytology* / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology*; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D013234:Stem Cells / Q000166:cytology* / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D015415:Biomarkers